Latest Period
Q2 2026
Security Snapshot
Lineage Cell Therapeutics, Inc. - Common Stock (LCTX) Institutional Ownership
CUSIP: 53566P109
13F Institutional Holders and Ownership History from Q2 2019 to Q2 2026
Institutions Reporting
130
Shares (Excl. Options)
116,520,947
Price
$1.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- LCTX on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 116,520,947
- Total 13F value
- $152,658,055
- Portfolio coverage rank
- 0%
- Share change
- +4,858,452
- Value change
- +$4,731,493
- Number of holders
- 130
- Shares outstanding
- 248,782,811
- SEC-reported price per share
- $1.12
- Insider filing price
- $1.12
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LCTX - Lineage Cell Therapeutics, Inc. - Common Stock is tracked under CUSIP 53566P109.
- 130 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 128 to 130 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $176,471,820 to $152,658,055.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 130 institutions filings for Q2 2026.
Security key
53566P109
Latest holder period
Q2 2026
13F holders
130
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
LCTX full holder history
Lineage Cell Therapeutics, Inc. SEC filings
Lineage Cell Therapeutics, Inc. company facts
Lineage Cell Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 53566P109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
LCTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 23% | -5.6% | $97,763,723 | 57,848,357 | 0% | NEAL C. BRADSHER | 12 Nov 2025 | |
| BlackRock, Inc. | 5.3% | +430% | $17,272,991 | +$14,345,737 | 13,185,489 | +490% | BlackRock, Inc. | 30 Jun 2026 |
| Chernett Jorey | 5% | $13,848,454 | 11,445,003 | Chernett Jorey | 22 Sep 2025 |
As of 30 Jun 2026, 130 institutional investors reported holding 116,520,947 shares of Lineage Cell Therapeutics, Inc. - Common Stock (LCTX). This represents 47% of the company’s total 248,782,811 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
45%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 20% | 49,560,992 | 0% | 3.4% | $64,924,900 |
| BlackRock, Inc. | 5.3% | 13,186,895 | +241% | 0% | $17,274,832 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 9,054,918 | +8.9% | 0% | $11,861,943 |
| Defender Capital, LLC. | 2.7% | 6,598,899 | -1.9% | 2.8% | $8,644,558 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 5,299,457 | +110% | 0% | $6,944,050 |
| RAFFLES ASSOCIATES LP | 2.1% | 5,197,788 | -3.1% | 5.8% | $6,809,102 |
| FIFTH THIRD BANCORP | 1.8% | 4,600,000 | 0% | 0.01% | $6,026,000 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 3,018,567 | -46% | 0% | $3,954,323 |
| STATE STREET CORP | 0.93% | 2,314,180 | +112% | 0% | $3,031,576 |
| VANGUARD FIDUCIARY TRUST CO | 0.67% | 1,668,629 | +26% | 0% | $2,185,904 |
| NORTHERN TRUST CORP | 0.67% | 1,656,651 | +232% | 0% | $2,170,213 |
| MORGAN STANLEY | 0.59% | 1,471,462 | -21% | 0% | $1,927,615 |
| RENAISSANCE TECHNOLOGIES LLC | 0.54% | 1,344,829 | -37% | 0% | $1,761,726 |
| MARSHALL WACE, LLP | 0.52% | 1,282,347 | -58% | 0% | $1,679,875 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.51% | 1,273,311 | 0% | $1,668,037 | |
| UBS Group AG | 0.28% | 687,051 | -50% | 0% | $900,036 |
| RED CRANE WEALTH MANAGEMENT, LLC | 0.24% | 597,263 | 0% | 0.58% | $782,415 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.23% | 577,435 | +344% | 0% | $756,440 |
| BARCLAYS PLC | 0.2% | 508,668 | +29% | 0% | $666,354 |
| Squarepoint Ops LLC | 0.18% | 444,774 | +211% | 0% | $582,654 |
| GOLDMAN SACHS GROUP INC | 0.17% | 433,266 | -63% | 0% | $567,578 |
| CITADEL ADVISORS LLC | 0.17% | 426,169 | +225% | 0% | $558,282 |
| BANK OF AMERICA CORP /DE/ | 0.17% | 424,373 | +1.2% | 0% | $555,928 |
| Bank of New York Mellon Corp | 0.16% | 391,675 | +1587% | 0% | $513,094 |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 0.12% | 304,562 | 0% | $398,976 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
29
Latest
Q2 2026
Rows shown
1-25 of 29
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 116,520,947 | $152,658,055 | +$4,731,493 | $1.31 | 130 |
| 2026 Q1 | 111,689,972 | $176,471,820 | +$22,991,753 | $1.58 | 128 |
| 2025 Q4 | 101,657,149 | $169,765,856 | +$22,647,526 | $1.67 | 121 |
| 2025 Q3 | 87,923,479 | $148,572,802 | -$9,340,067 | $1.69 | 111 |
| 2025 Q2 | 97,785,816 | $88,366,897 | -$8,826,258 | $0.91 | 128 |
| 2025 Q1 | 109,349,495 | $49,687,946 | +$369,638 | $0.45 | 126 |
| 2024 Q4 | 107,111,044 | $53,827,848 | +$3,921,589 | $0.50 | 119 |
| 2024 Q3 | 94,568,251 | $85,611,699 | -$260,148 | $0.91 | 112 |
| 2024 Q2 | 94,431,242 | $94,175,668 | +$447,460 | $1.00 | 110 |
| 2024 Q1 | 93,427,423 | $138,270,047 | +$26,536,201 | $1.48 | 113 |
| 2023 Q4 | 75,708,353 | $82,523,932 | +$188,614 | $1.09 | 114 |
| 2023 Q3 | 75,504,077 | $89,104,877 | -$402,119 | $1.18 | 102 |
| 2023 Q2 | 75,637,865 | $106,648,039 | +$8,457,693 | $1.41 | 105 |
| 2023 Q1 | 69,793,059 | $104,687,354 | +$7,197,215 | $1.50 | 114 |
| 2022 Q4 | 65,070,787 | $76,138,155 | +$591,571 | $1.17 | 99 |
| 2022 Q3 | 64,712,443 | $73,129,667 | -$348,315 | $1.13 | 88 |
| 2022 Q2 | 64,980,785 | $102,682,821 | -$12,116,491 | $1.58 | 84 |
| 2022 Q1 | 72,831,378 | $112,314,619 | -$3,915,128 | $1.54 | 99 |
| 2021 Q4 | 73,975,180 | $181,237,026 | -$5,349,258 | $2.45 | 110 |
| 2021 Q3 | 75,827,690 | $191,741,083 | +$6,640,880 | $2.52 | 106 |
| 2021 Q2 | 73,147,470 | $208,518,897 | +$38,013,987 | $2.85 | 103 |
| 2021 Q1 | 60,314,515 | $141,778,049 | +$12,436,479 | $2.35 | 90 |
| 2020 Q4 | 55,072,841 | $96,924,151 | +$3,142,777 | $1.76 | 78 |
| 2020 Q3 | 53,561,495 | $50,165,088 | -$1,850,541 | $0.94 | 65 |
| 2020 Q2 | 55,701,303 | $48,461,276 | -$6,974,131 | $0.87 | 80 |